Vaccines, medicines and COVID-19 : how can WHO be given a stronger voice? / Germán Velásquez.
2022
RA644.C67
Linked e-resources
Linked Resource
Concurrent users
Unlimited
Authorized users
Open access
Document Delivery Supplied
Open access
Details
Title
Vaccines, medicines and COVID-19 : how can WHO be given a stronger voice? / Germán Velásquez.
Uniform Title
Vaccins, médicaments et brevets. English
ISBN
9783030891251 (electronic bk.)
3030891259 (electronic bk.)
9783030891244 (print)
3030891259 (electronic bk.)
9783030891244 (print)
Published
Cham, Switzerland : Springer, 2022.
Language
English
Description
1 online resource (xvi, 117 pages)
Item Number
10.1007/978-3-030-89125-1 doi
Call Number
RA644.C67
Dewey Decimal Classification
362.1962/414
Summary
This open access book is a collection of research papers on COVID-19 by Germán Velásquez from 2020 and early 2021 that help to answer the question: How can an agency like the World Health Organization (WHO) be given a stronger voice to exercise authority and leadership? The considerable health, economic and social challenges that the world faced at the beginning of 2020 with COVID-19 continued and worsened in many parts of the world in the second-half of 2020 and into 2021. Many of these countries and nations wanted to explore COVID-19 on their own, sometimes without listening to the main international health bodies such as WHO, an agency of the United Nations system with long-standing experience and vast knowledge at the global level and of which all countries in the world are members. In this single volume, the chapters present the progress of thinking and debate -- particularly in relation to drugs and vaccines -- that would enable a response to the COVID-19 pandemic or to subsequent crises that may arise. Among the topics covered: COVID-19 Vaccines: Between Ethics, Health and Economics Medicines and Intellectual Property: 10 Years of the WHO Global Strategy Re-thinking Global and Local Manufacturing of Medical Products After COVID-19 Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus COVID-19 Shock Intellectual Property and Access to Medicines and Vaccines The World Health Organization Reforms in the Time of COVID-19 Vaccines, Medicines and COVID-19: How Can WHO Be Given a Stronger Voice? is essential reading for negotiators from the 194 member countries of the World Health Organization (WHO); World Trade Organization (WTO) and World Intellectual Property Organization (WIPO) staff participating in these negotiations; academics and students of public health, medicine, health sciences, law, sociology and political science; and intergovernmental organizations and non-governmental organizations that follow the issue of access to treatments and vaccines for COVID-19.
Bibliography, etc. Note
Includes bibliographical references and index.
Access Note
Open access.
Digital File Characteristics
text file PDF
Source of Description
Online resource; title from PDF title page (SpringerLink, viewed January 7, 2022).
Series
SpringerBriefs in public health, 2192-3701
Available in Other Form
Print version: 9783030891244
Print version: 9783030891268
Print version: 9783030891268
Linked Resources
Record Appears in
Table of Contents
Chapter 1: COVID-19 Vaccines: Between Ethics, Health and Economics
Chapter 2: Medicines and Intellectual Property: 10 Years of the WHO Global Strategy
Chapter 3: Re-thinking Global and Local Manufacturing of Medical Products After COVID-19
Chapter 4: Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus COVID-19 Shock
Chapter 5: Intellectual Property and Access to Medicines and Vaccines
Chapter 6: The World Health Organization Reforms in the Time of COVID-19
Epilogue.
Chapter 2: Medicines and Intellectual Property: 10 Years of the WHO Global Strategy
Chapter 3: Re-thinking Global and Local Manufacturing of Medical Products After COVID-19
Chapter 4: Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus COVID-19 Shock
Chapter 5: Intellectual Property and Access to Medicines and Vaccines
Chapter 6: The World Health Organization Reforms in the Time of COVID-19
Epilogue.